Similar Stocks · Benchmarked Analysis · Peer Group

Peer Group Analysis

Configuration
Company Price d* Change d* Volume, Avg. k, d* Market Cap. d* Revenue Profit Net Earnings Free Cash Flow Dividend Yield P/E EPS Gross Margin % Net Margin % ROE % ROA % Quick Ratio % Shares Outstanding d*
Biotechnology Average - - - - - - 13,352.09 826.47 207.02 -155.73 32.92 0.00 19.4437 -0.46 -1.1104 -24.5123 -0.09 -0.08 7.8337 - -
Maximum - - - - - - 462,775.00 65,349.00 25,407.00 99,050.00 5,305.00 0.01 1,336.3467 6.70 3.0051 85.3485 0.38 8.35 61.5621 - -
Minimum - - - - - - 0.00 0.00 -1,175.00 -56,335.00 -1,185.00 0.00 -164.8536 -8.99 -101.7758 -1,444.7800 -1.56 -12.64 0.0007 - -
Apellis Pharmaceuticals, Inc. APLS 28.23 -0.02 -0.05% 683 vs. 2,426 3,512.00 172.00 -66.00 -133.00 -2,903.00 -0.5400 -27.6326 0.0000 0.8802 -0.3855 -0.2491 -0.0798 2.7985 124.00
United Therapeutics Corporation UTHR 397.09 -3.36 -0.84% 36 vs. 392 17,727.00 677.00 306.00 338.00 6,333.00 6.5200 8.7477 0.0000 0.8924 0.4524 0.0574 0.0472 3.5035 44.00
Incyte Corporation INCY 79.55 -0.93 -1.16% 242 vs. 1,865 15,325.00 880.00 169.00 209.00 329.00 0.7600 18.7480 0.0000 0.9308 0.1925 0.0314 0.0238 3.2913 192.00
Alnylam Pharmaceuticals, Inc. ALNY 262.47 -2.13 -0.81% 102 vs. 824 33,853.00 494.00 -65.00 -94.00 -7,075.00 -0.5200 -73.3326 0.0000 0.8665 -0.1334 0.3007 -0.0172 2.8593 128.00
Ultragenyx Pharmaceutical Inc. RARE 48.49 -0.22 -0.45% 56 vs. 719 4,477.00 108.00 -170.00 -203.00 -3,558.00 -2.0300 -5.7986 0.0000 0.7576 -1.5683 -1.2169 -0.1306 2.1127 92.00
Revolution Medicines, Inc. RVMD 58.05 -0.09 -0.15% 259 vs. 1,146 9,764.00 0.00 -116.00 -163.00 -1,253.00 -0.7000 -11.2467 0.0000 0.0000 0.0000 -0.0672 -0.0608 18.1763 168.00
*d means the data is delayed 15 minutes at minimum.
More Due Diligence
Compare Fundamentals
Leverage our visualization and data tables to compare over 25 years of financial data for AAPL and its peers.
Watchlist
Keep an eye one one or all of the stocks by building a new watchlist.
Intrinsic Values
Utilize our versatile Gordan Growth Model for RARE and its peers to uncover potential buy and sell opportunities.